451 related articles for article (PubMed ID: 16167546)
21. Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas.
Cassoni P; Senetta R; Castellano I; Ortolan E; Bosco M; Magnani I; Ducati A
Am J Surg Pathol; 2007 May; 31(5):760-9. PubMed ID: 17460461
[TBL] [Abstract][Full Text] [Related]
22. Expression of hypoxia-related tissue factors correlates with diminished survival of adjuvantly treated patients with chromosome 1p aberrant oligodendroglial neoplasms and therapeutic implications.
Birner P; Preusser M; Gelpi E; Berger J; Gatterbauer B; Ambros IM; Ambros PF; Acker T; Plate KH; Harris AL; Hainfellner JA
Clin Cancer Res; 2004 Oct; 10(19):6567-71. PubMed ID: 15475445
[TBL] [Abstract][Full Text] [Related]
23. Comparative analysis of NeuN immunoreactivity in primary brain tumours: conclusions for rational use in diagnostic histopathology.
Preusser M; Laggner U; Haberler C; Heinzl H; Budka H; Hainfellner JA
Histopathology; 2006 Mar; 48(4):438-44. PubMed ID: 16487366
[TBL] [Abstract][Full Text] [Related]
24. A rare case of extraventricular neurocytoma.
Sakurada K; Akasaka M; Kuchiki H; Saino M; Mori W; Sato S; Nakazato Y; Kayama T
Brain Tumor Pathol; 2007; 24(1):19-23. PubMed ID: 18095140
[TBL] [Abstract][Full Text] [Related]
25. Oligodendrogliomas with neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications.
Perry A; Scheithauer BW; Macaulay RJ; Raffel C; Roth KA; Kros JM
J Neuropathol Exp Neurol; 2002 Nov; 61(11):947-55. PubMed ID: 12430711
[TBL] [Abstract][Full Text] [Related]
26. Grade II oligodendroglioma localized to the corpus callosum.
Monaco EA; Armah HB; Nikiforova MN; Hamilton RL; Engh JA
Brain Tumor Pathol; 2011 Oct; 28(4):305-9. PubMed ID: 21833577
[TBL] [Abstract][Full Text] [Related]
27. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A;
Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167
[TBL] [Abstract][Full Text] [Related]
28. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?
Gadji M; Fortin D; Tsanaclis AM; Drouin R
Cancer Genet Cytogenet; 2009 Oct; 194(1):12-22. PubMed ID: 19737649
[TBL] [Abstract][Full Text] [Related]
29. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features.
Jenkinson MD; du Plessis DG; Smith TS; Joyce KA; Warnke PC; Walker C
Brain; 2006 Jul; 129(Pt 7):1884-91. PubMed ID: 16670176
[TBL] [Abstract][Full Text] [Related]
30. Central neurocytomas are genetically distinct from oligodendrogliomas and neuroblastomas.
Tong CY; Ng HK; Pang JC; Hu J; Hui AB; Poon WS
Histopathology; 2000 Aug; 37(2):160-5. PubMed ID: 10931240
[TBL] [Abstract][Full Text] [Related]
31. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes.
Jenkinson MD; Smith TS; Joyce K; Fildes D; du Plessis DG; Warnke PC; Walker C
Neurology; 2005 Jun; 64(12):2085-9. PubMed ID: 15985578
[TBL] [Abstract][Full Text] [Related]
32. Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype.
Jenkinson MD; Smith TS; Brodbelt AR; Joyce KA; Warnke PC; Walker C
J Magn Reson Imaging; 2007 Dec; 26(6):1405-12. PubMed ID: 17968881
[TBL] [Abstract][Full Text] [Related]
33. Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma.
Perry A; Aldape KD; George DH; Burger PC
Cancer; 2004 Nov; 101(10):2318-26. PubMed ID: 15470710
[TBL] [Abstract][Full Text] [Related]
34. Anaplastic astrocytoma and anaplastic oligodendroglioma occurring 6 years after subtotal resection of a central neurocytoma. Case report.
Kanamori M; Kumabe T; Watanabe M; Tominaga T
J Neurosurg; 2007 Jul; 107(1):185-9. PubMed ID: 17639893
[TBL] [Abstract][Full Text] [Related]
35. Anaplastic oligodendroglioma arising from the brain stem and featuring 1p/19q co-deletion.
Hewer E; Beck J; Vassella E; Vajtai I
Neuropathology; 2014 Feb; 34(1):32-8. PubMed ID: 23711170
[TBL] [Abstract][Full Text] [Related]
36. Imaging correlates of molecular signatures in oligodendrogliomas.
Megyesi JF; Kachur E; Lee DH; Zlatescu MC; Betensky RA; Forsyth PA; Okada Y; Sasaki H; Mizoguchi M; Louis DN; Cairncross JG
Clin Cancer Res; 2004 Jul; 10(13):4303-6. PubMed ID: 15240515
[TBL] [Abstract][Full Text] [Related]
37. Intraoperative imprint cytology of central neurocytoma: The great oligodendroglioma mimicker.
Klysik M; Gavito J; Boman D; Miranda RN; Hanbali F; De Las Casas LE
Diagn Cytopathol; 2010 Mar; 38(3):202-7. PubMed ID: 19795492
[TBL] [Abstract][Full Text] [Related]
38. Leptomeningeal dissemination of a pediatric neoplasm with 1p19q deletion showing mixed immunohistochemical features of an oligodendroglioma and neurocytoma.
Rhiew RB; Manjila S; Lozen A; Guthikonda M; Sood S; Kupsky WJ
Acta Neurochir (Wien); 2010 Aug; 152(8):1425-9. PubMed ID: 20446099
[TBL] [Abstract][Full Text] [Related]
39. Extraventricular neurocytoma presenting with intratumoral hemorrhage.
Ritz R; Roser F; Bornemann A; Hahn U; Freudenstein D
Clin Neuropathol; 2005; 24(3):101-5. PubMed ID: 15943160
[TBL] [Abstract][Full Text] [Related]
40. [Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice].
Fontaine D; Vandenbos F; Lebrun C; Paquis V; Frenay M
Rev Neurol (Paris); 2008; 164(6-7):595-604. PubMed ID: 18565359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
